BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors

In Chronic Myeloid Leukemia (CML), successful treatment requires accurate molecular monitoring to evaluate disease response and provide timely interventions for patients failing to achieve the desired outcomes. We wanted to determine whether measuring BCR-ABL1 mRNA doubling-times (DTs) could disting...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Front Oncol
Prif Awduron: Pennisi, Maria Stella, Stella, Stefania, Vitale, Silvia Rita, Puma, Adriana, Di Gregorio, Sandra, Romano, Chiara, Tirrò, Elena, Massimino, Michele, Antolino, Agostino, Siragusa, Sergio, Mannina, Donato, Impera, Stefana, Musolino, Caterina, Mineo, Giuseppe, Martino, Bruno, Zammit, Valentina, Di Raimondo, Francesco, Manzella, Livia, Stagno, Fabio, Vigneri, Paolo
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2019
Pynciau:
Oncology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6700306/
https://ncbi.nlm.nih.gov/pubmed/31456947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00764
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg